The analysis results indicated that MM-Lip-Rg3/PNS can treat ischemic stroke by reducing cell apoptosis, inflammatory response, and oxidative stress through multiple targets (including AKT1, VEGFA, EGFR, CASP3, STAT3, and MAPK1) and multiple pathways (including PI3K/Rap1/cAMP/IL-17/TNF signaling pathway), as confirmed through in vivo animal experiments. Here, MAPK1 is linked to ischemic stroke.